No Data
CERo Therapeutics Received A Letter From Nasdaq Notifying The Company That It Had Not Regained Compliance With The MVLS Requirement Within The Cure Period; Nasdaq Has Determined To Delist The Company's Securities From Nasdaq On November 8, 2024; On...
Express News | Cero Therapeutics Holdings Inc - Fails to Regain Compliance With Nasdaq Mvls Requirement
Express News | Cero Therapeutics Holdings Inc Files for Resale of up to 713.6 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
CERo Therapeutics Announces Submission Of IND Clinical Hold Complete Response Letter; Adjusts Previous Guidance About Potential Entry Into The Clinic From 2024 To Early 2025; Recently Disclosed Our Cash Balance Of $3.2M As Of September 30, 2024
Express News | Cero Therapeutics Holdings: To Adjust Our Previous Guidance About Potential Entry Into Clinic From 2024 to Early 2025
Express News | Cero Therapeutics, Inc. Provides Corporate Update
No Data
No Data
if they dilute after the split
